Pancreatic Cancer Research

ResearcherOslo University HospitalActive in the last 2 years

Giuseppe Fusai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8784-6919; OpenAlex author ID A5033623007. Sources: OpenAlex.

Their work

Papers
25 (first author 1, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
125
Papers, trials and grants by year

2013: 1 paper · 2014: 3 papers · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 4 papers · 2024: 3 papers · 2025: 5 papers · 2026: 1 paper

Papers 25

  1. ASO Visual Abstract: Survival Benefit of Surgery Versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18479-z↗
  2. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  3. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  4. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  5. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  6. Survival Benefit of Surgery versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18212-w↗
  7. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
  8. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  9. Identification of a serum proteomic biomarker panel using diagnosis specific ensemble learning and symptoms for early pancreatic cancer detection. Co-author DOI 10.1371/journal.pcbi.1012408↗
  10. Role of circulating exosomal biomarkers and their diagnostic accuracy in pancreatic cancer. Last author DOI 10.1002/jgh3.12848↗
  11. Oncological outcomes after pancreatoduodenectomy for pancreatic ductal adenocarcinoma in octogenarians: case-control study. Co-author DOI 10.1093/bjsopen/zrad053↗
  12. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  13. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  14. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  15. Risk and Predictors of Postoperative Morbidity and Mortality After Pancreaticoduodenectomy for Pancreatic Neuroendocrine Neoplasms: A Comparative Study With Pa… Last author DOI 10.1097/mpa.0000000000001273↗
  16. Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6391-z↗
  17. Correction to: Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6442-5↗
  18. Impact of portal vein infiltration and type of venous reconstruction in surgery for borderline resectable pancreatic cancer. Last author DOI 10.1002/bjs.10580↗
  19. Demonstration of Calreticulin Expression in Hamster Pancreatic Adenocarcinoma with the Use of Fluorescent Gold Quantum Dots. Co-author PMID 26976972↗
  20. Outcome after pancreaticoduodenectomy for T3 adenocarcinoma: A multivariable analysis from the UK Vascular Resection for Pancreatic Cancer Study Group. Last author DOI 10.1016/j.ejso.2015.08.158↗
  21. Preoperative Gemcitabine-based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer. First author DOI 10.1097/sla.0000000000000685↗
  22. Resection versus other treatments for locally advanced pancreatic cancer. Last author DOI 10.1002/14651858.cd010244.pub2↗
  23. Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study. Last author DOI 10.1016/j.jamcollsurg.2013.11.017↗
  24. Obesity and pancreatic cancer. Last author DOI 10.1016/j.suronc.2014.02.003↗
  25. Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated wit… Co-author DOI 10.1111/hpb.12019↗

Closest collaborators

The 25 strongest of 125 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 7 shared papers, 2018–2026 · strength 0.85
  2. Ugo Boggi · 5 shared papers, 2018–2026 · strength 0.62
  3. Emanuele F. Kauffmann · 3 shared papers, 2023–2026 · strength 0.52
  4. Riccardo Casadei · 3 shared papers, 2023–2026 · strength 0.52
  5. Alessandro Zerbi · 3 shared papers, 2023–2026 · strength 0.52
  6. Allegra Ripolli · 2 shared papers, 2025–2026 · strength 0.41
  7. Kongyuan Wei · 2 shared papers, 2025–2026 · strength 0.41
  8. Sergio Alfieri · 2 shared papers, 2025–2026 · strength 0.41
  9. V. Egorov · 2 shared papers, 2025–2026 · strength 0.41
  10. Gregory G. Tsiotos · 2 shared papers, 2025–2026 · strength 0.41
  11. Yuichi Nagakawa · 2 shared papers, 2025–2026 · strength 0.41
  12. Niccolò Napoli · 2 shared papers, 2025–2026 · strength 0.41
  13. Benedetto Ielpo · 2 shared papers, 2025–2026 · strength 0.41
  14. Elena B. Rangelova · 2 shared papers, 2025–2026 · strength 0.41
  15. Emilio Vicente · 2 shared papers, 2025–2026 · strength 0.41
  16. Roberto Coppola · 2 shared papers, 2025–2026 · strength 0.41
  17. Keith John Roberts · 3 shared papers, 2020–2025 · strength 0.37
  18. Rupaly Pandé · 3 shared papers, 2020–2025 · strength 0.37
  19. Tobias Keck · 3 shared papers, 2020–2025 · strength 0.33
  20. Thilo Hackert · 3 shared papers, 2020–2025 · strength 0.33
  21. Giovanni Butturini · 3 shared papers, 2020–2025 · strength 0.33
  22. Bas Groot Koerkamp · 3 shared papers, 2020–2025 · strength 0.33
  23. Frederik Christiaan Berrevoet · 4 shared papers, 2018–2025 · strength 0.33
  24. Mickaël Lesurtel · 4 shared papers, 2018–2025 · strength 0.33
  25. Marco Del Chiaro · 4 shared papers, 2018–2025 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.